MedTrace Logo

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers

NCT07598968 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-05-20

No results posted yet for this study

Summary

This clinical trial is a two-arm, open-label, single-sequence, multiple oral dosings, cross-over design clinical trial to evaluate the safety and pharmacokinetic characteristics of HL1113-R1 and HL1113-R2 in healthy adult volunteers

Conditions

Interventions

DRUG

Test group 1

* Period 1: HL1113-R1, once daily, administered for 7 days * Period 2: HL1113-R1 + HL1113-R2 once daily, administered for 7 days

DRUG

Test group 2

* Period 1: HL1113-R2, once daily, administered for 5 days * Period 2: HL1113-R2 + HL1113-R1 once daily, administered for 7 days

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-18
Primary Completion
2023-07-12
Completion
2023-07-12

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07598968 on ClinicalTrials.gov